Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in BFLY.

← Back to Free Index

BFLY

Analysis as of: 2026-07-14

Butterfly Network, Inc.

Butterfly Network sells handheld ultrasound devices, cloud workflow software, and related services, and licenses its semiconductor-based ultrasound platform to partners.

ai hardware healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Platform upside needs mix shift proof

The opportunity is real because one regulated ultrasound chip can monetize across devices, workflow, home care, and partner licensing. The stock case is narrower: those higher-margin layers must scale fast enough to outrun hardware competition and justify today’s valuation.

Analysis

Thesis

Butterfly can grow far faster than a normal device company if its handheld ultrasound chip becomes the control point for regulated imaging workflows, home-care protocols, and Embedded partner products; the stock works only if those higher-margin layers scale before incumbents turn handheld ultrasound into a bundled feature.

Last Economy Alignment

AI lowers training friction and expands who can capture useful scans, so Butterfly can sell more regulated devices and workflow software. But it does not own a core compute or data monopoly, and hardware bundling from larger imaging vendors can still cap value capture.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.0x (from 5 most recent analyses)

Reasoning

This can be a very good business and still only a decent stock if it remains mainly a premium probe vendor. The upside case works when the same chip platform keeps adding higher-value layers—enterprise workflow, home-care protocols, and Embedded licensing—so revenue grows faster than headcount. I still assume multiple compression from today’s rich starting point, so most of the five-year return must come from execution rather than sentiment.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not whether the device works; it does. The real risk is whether Butterfly can convert a hardware lead into recurring, regulated workflow and licensing economics before incumbent vendors bundle away the handheld advantage. Regulatory gates, concentrated supply, and a valuation that already assumes meaningful platform success make execution timing crucial.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No new material operating disclosures were posted by the company in the last 7-10 days.
The July 2, 2026 Brazil launch remains the freshest business update and modestly expands international reach.
As of July 14, 2026, the investor relations events page still did not show a posted Q2 2026 earnings date, leaving the next major catalyst close but unscheduled.
A previously disclosed founder-related 10b5-1 selling window begins on July 14, 2026, creating possible technical share-supply pressure without changing the operating thesis.

Forecast update

Recent evidence makes the platform path more tangible: Embedded partner visibility, Brazil market entry, and compliance progress support a somewhat broader revenue bridge than before.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.36

They control a real bottleneck—a cleared handheld ultrasound device plus the workflow and compliance rails around it—so AI should make their product easier to use and more valuable. The risk is that bigger imaging vendors can copy enough of the handheld experience and use broader hospital relationships to squeeze the economics.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$7.06

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research